- A phase 3 trial evaluating a combination of Exelixis' ( NASDAQ: EXEL ) Cabometyx (cabozantinib) and Roche ( OTCQX:RHHBY ) Genentech unit's Tecentriq (atezolizumab) in locally advanced or metastatic renal cell carcinoma has failed.
- The CONTACT-03 study was evaluating the combination in patients who were unsuccessful on immune checkpoint inhibitor therapy vs. Cabometyx.
- The primary endpoint of progression-free survival was not met.
- Exelixis ( EXEL ) did not provide details on study results, but said they would be presented at a future medical meeting .
- Read why Seeking Alpha contributor Que Capital rates Exelixis ( EXEL ) a buy.
For further details see:
Exelixis Cabometyx + Tecentriq late-stage trial fails in advanced kidney cancer